Crimson Tide PLC Contract Win (9444V)
April 20 2021 - 1:00AM
UK Regulatory
TIDMTIDE
RNS Number : 9444V
Crimson Tide PLC
20 April 2021
20 April 2021
Crimson Tide agrees three year SaaS contract with
World Federation of Haemophilia
Crimson Tide ("Crimson Tide" or "the Company" (AIM:TIDE), the
provider of mpro5 is pleased to announce that it has signed a three
year agreement with the World Federation of Haemophilia (WFH). This
follows the successful completion of the pilot phase announced by
the Company on January 26, 2021.
The agreement will initially enable up to 100 clinicians
globally to use mpro5 to scan pharmaceuticals, verifying their
expiry and authenticity, and allowing the WFH to gain real-time
insights into product usage. The mpro5 platform will be integrated
into WFH's DPUMS system enabling real-time data captured from mpro5
to be available to all users around the world, replacing the
ineffective existing paper-based data input..
mpro5 provides barcode scanning, data analysis, and cloud-based
services via Microsoft Azure, renowned for its reliability,
scalability and security. This enables real-time information,
automated alerting, and integration capabilities with the existing
systems of the WFH, driving a more efficient, transparent, and
safer supply chain. mpro5 has been used in healthcare for many
years in the verification and patient management for the National
Coagulation Centre (NCC) in Ireland. It has also been used in
verification of counterfeit drugs for the World Health Organisation
in Africa and Asia.
The WFH is based in Montreal, Canada and its vision is that of
Treatment for All and that one day, all people with a bleeding
disorder will enjoy a more certain future filled with promise, no
matter where they live. The mission of the WFH is to improve and
sustain care for people with inherited bleeding disorders around
the world. In order to achieve this, the organisation actively
pursues long-term relationships with individuals and organizations
who share the values inherent in their comprehensive development
model.
Barrie Whipp, Executive Chairman of Crimson Tide, said: "We are
delighted that we have been able to demonstrate the unique
qualities of mpro5 to the WFH in such a short space of time. This
supports our belief that there are significant opportunities to use
our solutions throughout the wider healthcare sector and to help
deliver improved patient outcomes. We look forward to working with
the WFH and supporting them in their outstanding work."
For further information:
Crimson Tide plc
Barrie Whipp / Luke Jeffrey +441892 542 444
finnCap (Nominated Adviser and Broker)
Corporate Finance: Julian Blunt / James Thompson +44 20 7220
0500
Corporate Broking: Andrew Burdis +44 20 7220 0500
Alma PR (Financial PR)
Josh Royston +44 7780 901979
For further information on Crimson Tide plc, see the website at:
www.crimsontide.co.uk/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
CNTGPUMCCUPGGAB
(END) Dow Jones Newswires
April 20, 2021 02:00 ET (06:00 GMT)
Crimson Tide (LSE:TIDE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Crimson Tide (LSE:TIDE)
Historical Stock Chart
From Apr 2023 to Apr 2024